Covered recipient · General Payments record
KETAN D DOSHI
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$22,329.56
243 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $14,957.50 | 4 |
| Food and Beverage | $4,297.95 | 224 |
| Travel and Lodging | $3,074.11 | 15 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KETAN D DOSHI
NPI 1750573069 · CMS profile ID 351845
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
OCALA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KETAN D DOSHI, NPI 1750573069, CMS profile ID 351845. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). KETAN D DOSHI, NPI 1750573069, CMS profile ID 351845. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- KETAN D DOSHI, NPI 1750573069, CMS profile ID 351845, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 243 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750573069?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
243 matching records · $22,329.56 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 243.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $205.72 | 04/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 640644349 | CMS |
| Merck Sharp & Dohme Corporation | $31.99 | 04/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695634267 | CMS |
| Seattle Genetics, Inc. | $21.45 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678793815 | CMS |
| Novartis Pharmaceuticals Corporation | $12.96 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659015335 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.06 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651428235 | CMS |
| Genentech USA, Inc. | $11.26 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681305019 | CMS |
| EMD Serono, Inc. | $12.92 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703000297 | CMS |
| Amgen Inc. | $23.73 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662602529 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $8.03 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628439051 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $0.86 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628441497 | CMS |
| Horizon Therapeutics plc | $15.45 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691365643 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $17.43 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628467853 | CMS |
| GENZYME CORPORATION | $24.57 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694015965 | CMS |
| TerSera Therapeutics LLC | $18.81 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699766427 | CMS |
| Lilly USA, LLC | $1.00 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657934641 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.87 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697412307 | CMS |
| TerSera Therapeutics LLC | $18.81 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699766425 | CMS |
| Lilly USA, LLC | $0.20 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657951785 | CMS |
| Lilly USA, LLC | $12.11 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657951787 | CMS |
| TESARO, Inc. | $3,500.00 | 04/06/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558293 | CMS |
| TESARO, Inc. | $50.00 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558295 | CMS |
| TESARO, Inc. | $53.70 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558297 | CMS |
| TESARO, Inc. | $49.97 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558299 | CMS |
| TESARO, Inc. | $24.31 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558301 | CMS |
| TESARO, Inc. | $22.96 | 04/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558303 | CMS |
| TESARO, Inc. | $240.87 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558283 | CMS |
| TESARO, Inc. | $59.26 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558285 | CMS |
| TESARO, Inc. | $139.54 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558287 | CMS |
| TESARO, Inc. | $209.46 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558289 | CMS |
| TESARO, Inc. | $389.84 | 04/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558291 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.55 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688751779 | CMS |
| Merck Sharp & Dohme Corporation | $13.76 | 04/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695397661 | CMS |
| Horizon Therapeutics plc | $16.68 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691365637 | CMS |
| Seattle Genetics, Inc. | $10.82 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678793791 | CMS |
| Genentech USA, Inc. | $14.09 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681293175 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.01 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651428225 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.39 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688761319 | CMS |
| EISAI INC. | $21.85 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697003445 | CMS |
| Genentech USA, Inc. | $14.51 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681191635 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $12.71 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628463899 | CMS |
| Merck Sharp & Dohme Corporation | $15.41 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695385801 | CMS |
| TESARO, Inc. | $87.26 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675558281 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651428219 | CMS |
| Seattle Genetics, Inc. | $7.16 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 678793789 | CMS |
| Amgen Inc. | $17.88 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662602541 | CMS |
| Novartis Pharmaceuticals Corporation | $21.18 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659015319 | CMS |
| Novartis Pharmaceuticals Corporation | $21.00 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659015323 | CMS |
| Novartis Pharmaceuticals Corporation | $16.02 | 03/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659015315 | CMS |
| Lilly USA, LLC | $15.24 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657948447 | CMS |
| E.R. Squibb & Sons, L.L.C. | $0.66 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651428213 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $401,567.60 | 27 |
| PY2024 | Principal investigator | $440,923.65 | 31 |
| PY2023 | Principal investigator | $223,882.93 | 22 |
| PY2022 | Principal investigator | $29,742.36 | 6 |
| PY2021 | Principal investigator | $67,286.76 | 6 |
| PY2020 | Principal investigator | $60,363.41 | 12 |
| PY2019 | Recipient | $8,450.00 | 1 |
| PY2019 | Principal investigator | $19,280.80 | 6 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
27 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,487.80 | 12/02/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202526320 |
| Principal investigator 1 | ABBVIE INC. | $1,596.42 | 12/02/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202526322 |
| Principal investigator 1 | Epizyme, Inc. | $2,762.91 | 12/01/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282339 |
| Principal investigator 1 | Epizyme, Inc. | $2,280.55 | 12/01/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282341 |
| Principal investigator 1 | Epizyme, Inc. | $2,280.55 | 12/01/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282343 |
| Principal investigator 1 | Epizyme, Inc. | $2,762.91 | 12/01/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282345 |
| Principal investigator 1 | Epizyme, Inc. | $2,280.55 | 12/01/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282347 |
| Principal investigator 1 | Epizyme, Inc. | $2,280.55 | 10/16/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282333 |
| Principal investigator 1 | Epizyme, Inc. | $2,762.91 | 10/16/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282335 |
| Principal investigator 1 | Epizyme, Inc. | $2,280.55 | 10/16/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282337 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $2,500.00 | 10/09/2025 | Non-covered Recipient Entity Ocala Oncology Center, Pl | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530869 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $88.99 | 09/30/2025 | Non-covered Recipient Entity Ocala Oncology Center | A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) | No dispute reported | 06/30/2026 | 1235995024 |
| Principal investigator 1 | Celgene Corporation | $10,240.00 | 08/27/2025 | Non-covered Recipient Entity Ocala Oncology Center | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222306215 |
| Principal investigator 1 | ABBVIE INC. | $19,991.00 | 05/01/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202480885 |
| Principal investigator 1 | ABBVIE INC. | $9,923.00 | 05/01/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202480887 |
| Principal investigator 1 | ABBVIE INC. | $32,697.00 | 05/01/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER PL | Study of Ibrutinib and Rituximab in Treatment NaAve Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202480889 |
| Principal investigator 1 | Epizyme, Inc. | $419.17 | 04/30/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282329 |
| Principal investigator 1 | Epizyme, Inc. | $2,945.16 | 04/30/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282331 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $889.38 | 04/24/2025 | Non-covered Recipient Entity Ocala Oncology Center, Pl | A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy | No dispute reported | 06/30/2026 | 1236530864 |
| Principal investigator 1 | Eli Lilly and Company | $1,268.96 | 04/23/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER, P.L. | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187888850 |
| Principal investigator 1 | Epizyme, Inc. | $2,591.59 | 03/20/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282327 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $13,039.34 | 03/19/2025 | Non-covered Recipient Entity Ocala Oncology Center, Pl | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | No dispute reported | 06/30/2026 | 1236530859 |
| Principal investigator 1 | Epizyme, Inc. | $156.00 | 03/07/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282325 |
| Principal investigator 1 | Epizyme, Inc. | $4,082.40 | 02/19/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282321 |
| Principal investigator 1 | Epizyme, Inc. | $2,762.91 | 02/19/2025 | Non-covered Recipient Entity Ocala Oncology Center | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | No dispute reported | 06/30/2026 | 1184282323 |
| Principal investigator 1 | Eli Lilly and Company | $248,197.00 | 01/28/2025 | Non-covered Recipient Entity OCALA ONCOLOGY CENTER, P.L. | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187888848 |
| Principal investigator 1 | Celgene Corporation | $23,000.00 | 01/24/2025 | Non-covered Recipient Entity Ocala Oncology Center | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222306293 |